Shenzhen Beimei pharmaceutics Co. Limited is a well-established, innovation-driven specialty pharma with a focus on pediatric prescription medicines in China. The company was established in 2004. It is a Shenzhen High-tech Enterprise, a Small and Medium-Sized Scientific and Technological Enterprise, and a National High-tech Cultivational Enterprise.
In the past 14 years, the company has been developed from the initial regional agents to having our own centralized research and development, manufacturing and medical services. The company has achieved sustainable and rapid growth with a turnover compound annual growth rate (CAGR) of 23.74% for past five years，and the company's turnover was approximately RMB 100 million in 2018.
The company is committed to offering competitive products and services to meet China's unmet medical needs. The company focuses on the research and development and Licensing-in pediatric prescription products.
So far the company has formed an integrated structure of products, created a successful line of children’s medicines centered on Respiratory, Nervous system, Digestive system, Anti-infection, Dermatology, Immune system and etc. There are 3 products under development，entering the process of scale-up.
The company has successfully introduced 1 product from the well-known Indian company. The product is an oral solution for first-line treatment of epilepsy, now it is in the process of registration in China. At the same time, we are in the process of contract signing with several companies for a number of products. We ‘ll continue to develop and invest on 3-5 products per year to bring more effective disease treatment drugs to Chinese doctors and patients.
We have two business models, including the Academic Oriented Promotion Model and Commercial Promotion Model. There are close to 2,000 reps are working for us. And our network has covered more than 600 children's hospitals and 1,000 general hospitals throughout China.
Furthermore, the company has established long-term good cooperative relationships with nearly 10 top national pediatric academic leaders, and is working on a multi-center post-marketing clinical study on our main product “Sultamicillin for Suspension” with 8 top children's hospitals, including Beijing Children's Hospital and Peking University First Hospital, etc.
CEO Ms Wu Guangmei, sales directors, marketing directors and other core marketing executives had worked for large-scale listed pharmaceutical domestic or international enterprises, including Pfizer, Livzon Group, China Medical System, Kingworld Medicines Group, etc., and all have a deep understanding about the Chinese pharmaceutical industry, its rules and marketing operations.
We have professional R&D team, the team leader Doctor Ren, the R&D director from Joincare Group. We also have professional BD, RA and legal team who have many years of experiences in importing medicines, registration and legal affairs, as well as cooperating with a number of large international pharmaceutical companies to introduce products.
With the principle of 'offering the most outstanding pediatric medicines', we will continuously develop new products and expand marketing, promotion and sales network to become the leading pediatric medicine enterprise in China, and to create higher value for partners and ourselves. We will do our best to devote ourselves to the health of children in China.